ARS Pharmaceuticals, Inc. (SPRY) Q3 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Ars Pharmaceuticals, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:03.875 Good morning, and welcome to ARS Pharmaceuticals conference call. 00:00:03.875 -- 00:00:07.118 At this time, all participants are in a listen-only mode. 00:00:07.118 -- 00:00:10.782 After the company's prepared remarks, we will open the line for questions. 00:00:10.782 -- 00:00:14.426 Please be advised that today's conference is being recorded. 00:00:14.426 -- 00:00:18.009 I'll now turn the call over to Justin Chokmah, Chief Business Officer. 00:00:18.009 -- 00:00:20.390 Please go ahead. 00:00:21.092 -- 00:00:26.187 Good morning, and thank you for joining our third quarter 2025 earnings conference call. 00:00:26.187 -- 00:00:31.374 With me on the call are Richard Lowenthal, our co-founder, president, and CEO, 00:00:31.374 -- 00:00:36.901 Eric Paris, our chief commercial officer, and Kathy Scott, our CFO. 00:00:36.901 -- 00:00:42.448 This morning, we issued a press release detailing financial results and commercial highlights. 00:00:42.448 -- 00:00:46.934 That press release and the slide presentation, which we'll refer to today during today's 00:00:46.934 -- 00:00:53.601 call, are available in the investors and media section of our website at ars-pharma.com. 00:00:54.605 -- 00:00:59.569 Before we begin, please note that today's remarks and slide presentation may contain 00:00:59.569 -- 00:01:03.953 forward-looking statements. Actual results may differ materially. 00:01:03.953 -- 00:01:09.498 Please refer to our press release and SEC filings for further risk disclosures. 00:01:09.498 -- 00:01:12.781 With that, I'll turn the call over to Rich. 00:01:12.781 -- 00:01:17.024 Thank you, Justin. Good morning, everybody, and thank you for joining us to discuss what 00:01:17.024 -- 00:01:22.269 has been a pivotal quarter for ARS Pharma, driv...